| MeSH term | MeSH ID | Detail |
|---|---|---|
| Abnormalities, Multiple | D000015 | 13 associated lipids |
| Abortion, Spontaneous | D000022 | 12 associated lipids |
| Acne Vulgaris | D000152 | 35 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
| Adrenal Insufficiency | D000309 | 3 associated lipids |
| Akinetic Mutism | D000405 | 1 associated lipids |
| Albuminuria | D000419 | 18 associated lipids |
| Alopecia | D000505 | 14 associated lipids |
| Alopecia Areata | D000506 | 6 associated lipids |
| Alzheimer Disease | D000544 | 76 associated lipids |
| Amenorrhea | D000568 | 4 associated lipids |
| Amputation, Traumatic | D000673 | 2 associated lipids |
| Anemia | D000740 | 21 associated lipids |
| Anemia, Aplastic | D000741 | 6 associated lipids |
| Anemia, Hemolytic | D000743 | 4 associated lipids |
| Anemia, Hemolytic, Autoimmune | D000744 | 5 associated lipids |
| Anemia, Refractory | D000753 | 3 associated lipids |
| Anemia, Refractory, with Excess of Blasts | D000754 | 2 associated lipids |
| Aneurysm, Dissecting | D000784 | 2 associated lipids |
| Angiolymphoid Hyperplasia with Eosinophilia | D000796 | 1 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Gerber DA et al. | Immunosuppressive agents: recent developments in molecular action and clinical application. | 1998 | Transplant. Proc. | pmid:9636637 |
| Goulet O et al. | Small bowel transplantation alone or with the liver in children: changes by using FK506. | 1998 | Transplant. Proc. | pmid:9636636 |
| Stratta RJ | Late acute rejection episodes after vascularized pancreas transplantation. | 1998 | Transplant. Proc. | pmid:9636633 |
| Gruessner RW | Antibody induction therapy in pancreas transplantation. | 1998 | Transplant. Proc. | pmid:9636632 |
| Burke GW et al. | Use of tacrolimus and mycophenolate mofetil for pancreas-kidney transplantation with or without OKT3 induction. | 1998 | Transplant. Proc. | pmid:9636627 |
| Peddi VR et al. | Long-term kidney and pancreas function with tacrolimus immunosuppression following simultaneous kidney and pancreas transplantation. | 1998 | Transplant. Proc. | pmid:9636626 |
| Bruce DS et al. | Tacrolimus/mycophenolate provides superior immunosuppression relative to neoral/mycophenolate in synchronous pancreas-kidney transplantation. | 1998 | Transplant. Proc. | pmid:9636625 |
| Ciancio G et al. | Use of intravenous tacrolimus to reverse vascular rejection in kidney and simultaneous kidney-pancreas transplantation. | 1998 | Transplant. Proc. | pmid:9636624 |
| Schulz T et al. | Tacrolimus/mycophenolate mofetil/steroid-based immunosuppression after pancreas-kidney transplantation with single shot antithymocyte globulin. | 1998 | Transplant. Proc. | pmid:9636623 |
| Walker S et al. | Clinical use and bioavailability of tacrolimus in heart-lung and double lung transplant recipients with cystic fibrosis. | 1998 | Transplant. Proc. | pmid:9636618 |
| Wiebe K et al. | FK506 rescue therapy in lung transplantation. | 1998 | Transplant. Proc. | pmid:9636613 |
| Lipson DA et al. | Conversion to tacrolimus (FK506) from cyclosporine after orthotopic lung transplantation. | 1998 | Transplant. Proc. | pmid:9636612 |
| McAlister VC et al. | Cost of liver transplantation using tacrolimus. | 1998 | Transplant. Proc. | pmid:9636611 |
| Mueller AR et al. | Influence of immunosuppression on patient outcome after liver transplantation. | 1998 | Transplant. Proc. | pmid:9636608 |
| Maggard M et al. | Incidence of acute rejection in African-American liver transplant recipients. | 1998 | Transplant. Proc. | pmid:9636607 |
| Charco R et al. | Hypercholesterolemia in long-term survivors of liver transplantation: a comparison between cyclosporine and FK 506. | 1998 | Transplant. Proc. | pmid:9636605 |
| Nakamura M et al. | Clinical and radiological features of two cases of tacrolimus-related posterior leukoencephalopathy in living related liver transplantation. | 1998 | Transplant. Proc. | pmid:9636600 |
| Ghobrial RM et al. | Retransplantation for recurrent hepatitis C following tacrolimus or cyclosporine immunosuppression. | 1998 | Transplant. Proc. | pmid:9636597 |
| Platz KP et al. | Indications for mycophenolate mofetil therapy in hepatitis C-patients undergoing liver transplantation. | 1998 | Transplant. Proc. | pmid:9636596 |
| Lang M et al. | Impact of immunosuppression in liver transplantation across a positive crossmatch. | 1998 | Transplant. Proc. | pmid:9636595 |
| Mueller AR et al. | Does initial graft function influence the outcome after liver transplantation? | 1998 | Transplant. Proc. | pmid:9636594 |
| Cantarovich M et al. | Optimal time points for the prediction of the area-under-the-curve in liver transplant patients receiving tacrolimus. | 1998 | Transplant. Proc. | pmid:9636592 |
| Bekersky I et al. | Bioequivalence of a new strength tacrolimus capsule under development. | 1998 | Transplant. Proc. | pmid:9636591 |
| Liu WT et al. | In vitro generation of tacrolimus metabolites and their detection in whole blood. | 1998 | Transplant. Proc. | pmid:9636590 |
| Steinmueller T et al. | Effect of CsA versus FK 506 on insulin sensitivity and insulin response using a modeling technique. | 1998 | Transplant. Proc. | pmid:9636589 |
| Klupp J et al. | Risk and benefit of antibody induction therapy in combination with tacrolimus immunosuppression after liver transplantation. | 1998 | Transplant. Proc. | pmid:9636585 |
| Abe M et al. | Successful prednisone withdrawal after living-related liver transplantation. | 1998 | Transplant. Proc. | pmid:9636584 |
| Langrehr JM et al. | Comparison of quadruple induction including ATG or IL-2R antibody with FK506-based therapy after liver transplantation. | 1998 | Transplant. Proc. | pmid:9636583 |
| Bilbao I et al. | Experience with neoral cyclosporine through the oral route in liver transplantation. | 1998 | Transplant. Proc. | pmid:9636580 |
| Pratschke J et al. | Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation: long-term results. | 1998 | Transplant. Proc. | pmid:9636575 |
| Rudich SM et al. | Immunosuppression using tacrolimus, mycophenolate, and prednisone following orthotopic liver transplantation: a single-center experience. | 1998 | Transplant. Proc. | pmid:9636574 |
| Ringe B et al. | Tacrolimus and mycophenolate mofetil in clinical liver transplantation: experience with a steroid-sparing concept. | 1998 | Transplant. Proc. | pmid:9636573 |
| Cai TH et al. | Improved immunosuppression with combination tacrolimus (FK506) and mycophenolic acid in orthotopic liver transplantation. | 1998 | Transplant. Proc. | pmid:9636572 |
| Taibi A et al. | Rescue FK506 therapy for acute rejection and early chronic rejection after liver transplantation: report of 14 cases. | 1998 | Transplant. Proc. | pmid:9636571 |
| Platz KP et al. | FK506 for primary and rescue therapy following liver transplantation. | 1998 | Transplant. Proc. | pmid:9636570 |
| Millis JM et al. | Successful use of tacrolimus for initial rejection episodes after liver transplantation. | 1998 | Transplant. Proc. | pmid:9636569 |
| Zervos XA et al. | Comparison of tacrolimus with neoral as primary immunosuppression in hepatitis C patients after liver transplantation. | 1998 | Transplant. Proc. | pmid:9636568 |
| Jain A et al. | Liver transplantation under tacrolimus in infants, children, adults, and seniors: long-term results, survival, and adverse events in 1000 consecutive patients. | 1998 | Transplant. Proc. | pmid:9636567 |
| Van Buren D et al. | Renal function in primary liver transplant recipients receiving neoral (cyclosporine) versus prograf (tacrolimus). | 1998 | Transplant. Proc. | pmid:9636566 |
| Wiesner RH | Long-term comparison of tacrolimus versus cyclosporine in liver transplantation. The US FK Study Group. | 1998 | Transplant. Proc. | pmid:9636565 |
| McDiarmid S et al. | One hundred children treated with tacrolimus after primary orthotopic liver transplantation. | 1998 | Transplant. Proc. | pmid:9636564 |
| Samuel D et al. | Tacrolimus (FK506)-based dual versus triple therapy following liver transplantation. | 1998 | Transplant. Proc. | pmid:9636563 |
| Rossi G et al. | Three-year follow-up of low dose tacrolimus oral therapy after liver transplantation: a single-centre experience. | 1998 | Transplant. Proc. | pmid:9636562 |
| Grewal HP et al. | Corticosteroid cessation 1 week following renal transplantation using tacrolimus/mycophenolate mofetil based immunosuppression. | 1998 | Transplant. Proc. | pmid:9636558 |
| Shapiro R et al. | Outcome after steroid withdrawal in renal transplant patients receiving tacrolimus-based immunosuppression. | 1998 | Transplant. Proc. | pmid:9636557 |
| Fitzsimmons WE et al. | Demographic considerations in tacrolimus pharmacokinetics. | 1998 | Transplant. Proc. | pmid:9636552 |
| Neylan JF | Effect of race and immunosuppression in renal transplantation: three-year survival results from a US multicenter, randomized trial. FK506 Kidney Transplant Study Group. | 1998 | Transplant. Proc. | pmid:9636551 |
| Kumar MS et al. | ATGAM versus OKT3 induction therapy in cadaveric kidney transplantation: patient and graft survival, CD3 subset, infection, and cost analysis. | 1998 | Transplant. Proc. | pmid:9636549 |
| Undre NA et al. | Pharmacokinetics of FK 506 and mycophenolic acid after the administration of a FK 506-based regimen in combination with mycophenolate mofetil in kidney transplantation. | 1998 | Transplant. Proc. | pmid:9636527 |
| Woodle ES et al. | Meta-analysis of FK 506 and mycophenolate mofetil refractory rejection trials in renal transplantation. Refractory Rejection Meta-Analysis Study Group. | 1998 | Transplant. Proc. | pmid:9636526 |